A new study published in the JAMA has revealed that for patients with relapsing-remitting multiple sclerosis (RRMS), high-dose immunosuppressive therapy (HDIT) with autologous hematopoietic cell transplant (HCT) is related with sustained remission and improvements in neurologic function. Most patients with RRMS who received disease-modifying therapies experience breakthrough disease. Autologous (i.e. using a patient's own cells) HCT has been studied in RRMS with the ...Tuesday, 30 December 2014
Autologous Hematopoietic Cell Transplant (HCT) Sends Multiple Sclerosis into Remission
A new study published in the JAMA has revealed that for patients with relapsing-remitting multiple sclerosis (RRMS), high-dose immunosuppressive therapy (HDIT) with autologous hematopoietic cell transplant (HCT) is related with sustained remission and improvements in neurologic function. Most patients with RRMS who received disease-modifying therapies experience breakthrough disease. Autologous (i.e. using a patient's own cells) HCT has been studied in RRMS with the ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment